GADD45B and non-small cell lung carcinoma: In contrast, compared to those for control siRNA-treated cells, the covered areas and migrated cells for each of the four human NSCLC cell lines decreased with treatment of TFAP2C siRNA, and the uncovered areas were significantly filled and cell migration capacity was recovered after further treatment with GADD45B or PMAIP1 siRNA (Fig. 6d–f).